A federal jury in the US District Court for the District of Delaware has found that Parse Biosciences — now a subsidiary of Netherlands-based Qiagen (NYSE: QGEN) — willfully infringed three patents licensed to Scale Biosciences, which Pleasanton, California-based 10x Genomics, Inc. (Nasdaq: TXG) acquired in 2025. The jury also rejected Parse's invalidity challenges to US Patent Nos. 10,626,442, 10,982,256, and 11,512,341, which are exclusively licensed from Roche Sequencing Solutions.
The jury awarded 10x Genomics USD 4.8 million in damages for infringement tied to Parse's Evercode Whole Transcriptome products, based on a 14% royalty rate on relevant sales through June 30, 2026.
The finding of willful infringement opens the door to enhanced damages and attorneys' fees in post-trial proceedings. 10x Genomics said it also intends to seek a permanent injunction barring further US sales of the infringing Evercode Whole Transcriptome products.
An injunction could materially affect Parse's position in single-cell transcriptomics, although the scope of any order will be determined by the court. Parse has continued to expand the Evercode platform under Qiagen ownership, including the April 2026 launch of FFPE-compatible barcoding technology and a next-generation immune profiling kit released in June. Whether those newer products fall within the scope of any eventual injunction remains unresolved.
The three patents at issue cover aspects of split-pool combinatorial barcoding, a method in which cells are fixed, distributed across multi-well plates, and sequentially labeled with oligonucleotide barcodes through multiple rounds of in-cell ligation to generate cell-specific molecular identifiers without relying on droplet-based microfluidics.